Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma

Cancer Letters

Volumn 275, Issue 1, 2009, Pages 109-116

  Li, Xiu Qin ^a   Zhang, Shu Lan ^a   Cai, Zhen ^b,c   Zhou, Yuan ^c   Ye, Tian Min ^c   Chiu, Jen Fu ^c  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

2DE; Ovarian epithelial serous cystadenocarinoma; Protein profile; Tumor associated proteins

Indexed keywords

PROTEIN PRX II; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYSTADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY EPITHELIAL SEROUS CYSTADENOCARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; WESTERN BLOTTING;

CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARY; PROTEOMICS; SILVER STAINING; TUMOR MARKERS, BIOLOGICAL;

EID: 58549090494     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.019     Document Type: Article

References (48)

1. Schildkraut J.M., and Thompson W.D. Familial ovarian cancer: a population-based case-control study. Am. J. Epidemiol. 128 (1988) 456-466
2. Bengtsson S., Krogh M., Szigyarto C.A., Uhlen M., Schedvins K., Silfversward C., Linder S., Auer G., Alaiya A., and James P. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J. Proteome Res. 6 (2007) 1440-1450
3. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics 3 (2004) 355-366
4. Wasinger V.C., Cordwell S.J., Cerpa-Poljak A., Yan J.X., Gooley A.A., Wilkins M.R., Duncan M.W., Harris R., Williams K.L., and Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16 (1995) 1090-1094
5. Wilkins M.R., Sanchez J.C., Gooley A.A., Appel R.D., Humphery-Smith I., Hochstrasser D.F., and Williams K.L. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13 (1996) 19-50
6. Lau A.T., and Chiu J.F. Proteomic and biochemical analyses of in vitro carcinogen-induced lung cell transformation: synergism between arsenic and benzo[a]pyrene. Proteomics 6 (2006) 1619-1630
7. He Q.Y., and Chiu J.F. Proteomics in biomarker discovery and drug development. J. Cell. Biochem. 89 (2003) 868-886
8. Qi Y.J., He Q.Y., Ma Y.F., Du Y.W., Liu G.C., Li Y.J., Tsao G.S., Ngai S.M., and Chiu J.F. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J. Cell. Biochem. (2008)
9. Hwa J.S., Park H.J., Jung J.H., Kam S.C., Park H.C., Kim C.W., Kang K.R., Hyun J.S., and Chung K.H. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J. Korean Med. Sci. 20 (2005) 450-455
10. Lee C.J., Ariztia E.V., and Fishman D.A. Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer. Crit. Rev. Clin. Lab. Sci. 44 (2007) 87-114
11. Ioachim E., Tsanou E., Briasoulis E., Batsis C., Karavasilis V., Charchanti A., Pavlidis N., and Agnantis N.J. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12 (2003) 111-119
12. Lau A.T., He Q.Y., and Chiu J.F. A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem. J. 382 (2004) 641-650
13. Bast Jr. R.C. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol. 21 (2003) 200s-205s
14. Morita A., Miyagi E., Yasumitsu H., Kawasaki H., Hirano H., and Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6 (2006) 5880-5890
15. Gagne J.P., Ethier C., Gagne P., Mercier G., Bonicalzi M.E., Mes-Masson A.M., Droit A., Winstall E., Isabelle M., and Poirier G.G. Comparative proteome analysis of human epithelial ovarian cancer. Proteome Sci. 5 (2007) 16
16. Gagne J.P., Gagne P., Hunter J.M., Bonicalzi M.E., Lemay J.F., Kelly I., Le Page C., Provencher D., Mes-Masson A.M., Droit A., et al. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol. Cell. Biochem. 275 (2005) 25-55
17. Jones M.B., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E.C., and Petricoin III E.F. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2 (2002) 76-84
18. Wang J., Zhang X., Ge X., Guo H., Xiong G., and Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol. Oncol. 1 (2008)
19. Cable S., Keller J.M., Colin S., Haffen K., Kedinger M., Parache R.M., and Dauca M. Peroxisomes in human colon carcinomas. A cytochemical and biochemical study. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 62 (1992) 221-226
20. Suto K., Kajihara-Kano H., Yokoyama Y., Hayakari M., Kimura J., Kumano T., Takahata T., Kudo H., and Tsuchida S. Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. J. Cancer Res. Clin. Oncol. 125 (1999) 83-88
21. He Q.Y., Zhou Y., Wong E., Ehlen T.G., Auersperg N., Chiu J.F., and Wong A.S. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. Gynecol. Oncol. 98 (2005) 68-76
22. Chae H.Z., Kim I.H., Kim K., and Rhee S.G. Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J. Biol. Chem. 268 (1993) 16815-16821
23. Chae H.Z., Robison K., Poole L.B., Church G., Storz G., and Rhee S.G. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc. Natl. Acad. Sci. USA 91 (1994) 7017-7021
24. Chae H.Z., Uhm T.B., and Rhee S.G. Dimerization of thiol-specific antioxidant and the essential role of cysteine 47. Proc. Natl. Acad. Sci. USA 91 (1994) 7022-7026
25. Rhee S.G., Kang S.W., Chang T.S., Jeong W., and Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52 (2001) 35-41
26. Seo M.S., Kang S.W., Kim K., Baines I.C., Lee T.H., and Rhee S.G. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275 (2000) 20346-20354
27. Choi J.H., Kim T.N., Kim S., Baek S.H., Kim J.H., Lee S.R., and Kim J.R. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 22 (2002) 3331-3335
28. Watabe S., Hiroi T., Yamamoto Y., Fujioka Y., Hasegawa H., Yago N., and Takahashi S.Y. SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur. J. Biochem. 249 (1997) 52-60
29. Nonn L., Berggren M., and Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 1 (2003) 682-689
30. Wonsey D.R., Zeller K.I., and Dang C.V. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc. Natl. Acad. Sci. USA 99 (2002) 6649-6654
31. Araki M., Nanri H., Ejima K., Murasato Y., Fujiwara T., Nakashima Y., and Ikeda M. Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J. Biol. Chem. 274 (1999) 2271-2278
32. Noh D.Y., Ahn S.J., Lee R.A., Kim S.W., Park I.A., and Chae H.Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21 (2001) 2085-2090
33. Kinnula V.L., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang S.W., Rhee S.G., and Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 196 (2002) 316-323
34. Chang J.W., Jeon H.B., Lee J.H., Yoo J.S., Chun J.S., Kim J.H., and Yoo Y.J. Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 289 (2001) 507-512
35. Karihtala P., Mantyniemi A., Kang S.W., Kinnula V.L., and Soini Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 9 (2003) 3418-3424
36. Kinnula V.L., Paakko P., and Soini Y. Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Lett. 569 (2004) 1-6
37. Memon A.A., Chang J.W., Oh B.R., and Yoo Y.J. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect. Prev. 29 (2005) 249-255
38. Qi Y., Chiu J.F., Wang L., Kwong D.L., and He Q.Y. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5 (2005) 2960-2971
39. Ai J., Tan Y., Ying W., Hong Y., Liu S., Wu M., Qian X., and Wang H. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 6 (2006) 538-546
40. Neumann C.A., Krause D.S., Carman C.V., Das S., Dubey D.P., Abraham J.L., Bronson R.T., Fujiwara Y., Orkin S.H., and Van Etten R.A. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424 (2003) 561-565
41. Langdon S.P., and Smyth J.F. Inhibition of cell signalling pathways. Cancer Treat. Rev. 21 (1995) 65-89
42. Arts H.J., Hollema H., Lemstra W., Willemse P.H., De Vries E.G., Kampinga H.H., and Van der Zee A.G. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int. J. Cancer 84 (1999) 234-238
43. Kapranos N., Kominea A., Konstantinopoulos P.A., Savva S., Artelaris S., Vandoros G., Sotiropoulou-Bonikou G., and Papavassiliou A.G. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J. Cancer Res. Clin. Oncol. 128 (2002) 426-432
44. Korneeva I., Bongiovanni A.M., Girotra M., Caputo T.A., and Witkin S.S. IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. Int. J. Cancer 87 (2000) 824-828
45. Cappello F., Bellafiore M., Palma A., Marciano V., Martorana G., Belfiore P., Martorana A., Farina F., Zummo G., and Bucchieri F. Expression of 60-kD heat shock protein increases during carcinogenesis in the uterine exocervix. Pathobiology 70 (2002) 83-88
46. Cappello F., Bellafiore M., David S., Anzalone R., and Zummo G. Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix. Cancer Lett. 196 (2003) 35-41
47. Cappello F., Rappa F., David S., Anzalone R., and Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res. 23 (2003) 1325-1331
48. Kirchhoff S.R., Gupta S., and Knowlton A.A. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation 105 (2002) 2899-2904